PROJECTED COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS EXENATIDE BID FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK

被引：0
|
作者：
Wilson, B. P. [1 ]
Beaudet, A. [2 ]
Caputo, J. [3 ]
Timlin, L. [4 ]
机构：
[1] Eli Lilly & Co, London, Hants, England
[2] IMS Consulting Grp, Basel, Switzerland
[3] IMS Consulting Grp, London, England
[4] Eli Lilly & Co, London, Surrey, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1330
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A476 / A476
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [2] Exenatide once weekly for the treatment of type 2 diabetes
    Malone, James
    Trautmann, Michael
    Wilhelm, Ken
    Taylor, Kristin
    Kendall, David M.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (03) : 359 - 367
  • [3] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [4] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2018, 38 : 67 - 77
  • [5] Exenatide once weekly in type 2 diabetes
    Scheen, Andre J.
    [J]. LANCET, 2008, 372 (9645): : 1197 - 1198
  • [6] PROJECTED LONG-TERM CLINICAL AND ECONOMIC OUTCOMES OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Beaudet, A.
    Wilson, B.
    Caputo, J.
    Timlin, L.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A476 - A476
  • [7] Once-weekly exenatide as a treatment for Type 2 diabetes
    Schauerhamer, Marisa B.
    Gurgle, Holly
    McAdam-Marx, Carrie
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (06) : 611 - 626
  • [8] Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
    Chuang, L. H.
    Verheggen, B. G.
    Charokopou, M.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1127 - 1134
  • [9] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE
    Charokopou, M.
    Chuang, L.
    Verheggen, B.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [10] Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
    Pencek, R.
    Blickensderfer, A.
    Li, Y.
    Brunell, S. C.
    Chen, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (11) : 1021 - 1032
12345